Radiopharmaceutical CDMO Market: Rising Nuclear Medicine Demand Drives 9.3% CAGR Growth

As per the Radiopharmaceutical CDMO Market analysis conducted by the CMI Team, the global market for Radiopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) is set for strong expansion over the next decade. The global Radiopharmaceutical CDMO Market is expected to record a CAGR of 9.3% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 3.1 Billion, and by 2034, the valuation is anticipated to reach USD 7.2 Billion, driven by unprecedented demand for diagnostic and therapeutic radioisotopes, advancements in nuclear medicine, and accelerating investments in targeted radiotherapy.

Get Free Report Insights - Download Now @https://www.custommarketinsights.com/request-for-free-sample/?reportid=74645

➤Market Size

The Radiopharmaceutical CDMO Market continues to experience robust year-on-year growth, transforming from a niche segment within pharmaceutical manufacturing to a central infrastructure supporting precision oncology and advanced diagnostics. By 2034, the market will more than double its 2025 valuation, fueled by the rising use of theranostics, increased radioisotope production capabilities, and rapid expansion of global nuclear medicine networks.

➤Market Overview

The global radiopharmaceutical landscape is undergoing a significant structural shift. As pharmaceutical and biotech companies pivot toward personalized medicine and targeted therapies, radiopharmaceuticals-especially those based on isotopes like Actinium-225, Gallium-68, Technetium-99m, and Lutetium-177-are emerging as high-value assets.

CDMOs play an indispensable role in this transition by offering:

• End-to-end radiolabeling solutions
• GMP manufacturing
• Radioisotope handling expertise
• Regulatory support for radiotherapeutics
• Scalable cyclotron and reactor-based isotope production

This has made them a strategic extension of the R&D and commercial operations of pharma innovators. Increasing oncology applications and an expanding clinical pipeline are further accelerating market demand.

As radiopharmaceuticals require specialized facilities, complex logistics, and strict regulatory compliance, global demand for external CDMO partnerships continues to surge.

Customize This Report to Your Needs @ https://www.custommarketinsights.com/request-for-customization/?reportid=74645

➤Key Market Growth Drivers

1. Rapid Adoption of Targeted Radiotherapies
Breakthroughs in alpha- and beta-emitting therapeutic isotopes-such as Lu-177 and Ac-225-have significantly increased radiopharmaceutical pipelines. Targeted radionuclide therapy (TRT) is emerging as a mainstream cancer treatment, creating heavy manufacturing and supply-chain requirements that CDMOs are positioned to support.
2. Rising Global Incidence of Cancer & Neurological Disorders
Growing disease burdens associated with oncology and neurological disorders are driving strong demand for PET and SPECT diagnostics and novel therapeutic radiopharmaceuticals.
3. Supply Shortages of Key Isotopes
Chronic shortages of Technetium-99m, Actinium-225, and other isotopes are accelerating investments in alternative production routes and underserved geographies.
4. Industry Consolidation & Strategic CDMO Partnerships
Pharma companies are preferring outsourcing models due to high capital requirements and stringent nuclear handling regulations. As a result, radiopharmaceutical CDMOs are witnessing increased contract volumes.
5. Growth of Cyclotron Installations & Nuclear Reactor Modernization
Government initiatives and private investments into upgrading nuclear medicine infrastructure are enabling larger-scale and more consistent isotope production globally.

➤Analysis of Key Players -

Leading CDMOs and isotope manufacturers are implementing multi-layered strategies to support global supply-chain growth:

• Capacity Expansion: Large-scale additions of cyclotrons, hot cells, and radiochemistry suites.
• Diversification of Isotope Portfolios: Companies are expanding offerings in Lu-177, Ga-68, F-18, Ac-225, and other emerging isotopes.
• Global Facility Footprint Growth: Establishing new GMP manufacturing sites in the U.S., Europe, and APAC.
• Long-term Supply Agreements: Strategic, multi-year partnerships with major pharma companies for pipeline support.
• Advanced Labeling Technologies: Integration of automation, AI-driven quality control, and robotics for sterile radiolabeling.
• Regulatory Streamlining: Proactive collaboration with EMA, FDA, and IAEA to ensure compliance and faster approvals.

➤Leading Players

The Radiopharmaceutical CDMO Market is highly competitive, with a large number of product providers globally. Some of the key players in the market include:

• NorthStar Medical Radioisotopes
• Eckert & Ziegler
• ITM Isotope Technologies München SE
• Curium Pharma
• Cardinal Health
• SOFIE
• PharmaLogic
• Monrol (Eczacıbaşı Monrol)
• SpectronRx
• Ionetix Corporation
• Minerva Imaging
• Seibersdorf Labor GmbH
• Evergreen Theragnostics Inc.
• Global Medical Solutions
• GBI Biomanufacturing
• Others

➤Market Challenges & Opportunities

Challenges

• Limited global isotope supply, especially for Actinium-225
• High cost of establishing GMP radiopharmaceutical facilities
• Supply-chain risks related to short isotope half-life
• Stringent government and nuclear regulatory frameworks
• Shortage of skilled radiochemists and trained professionals

Opportunities

• Expansion into emerging markets with minimal radiopharmaceutical infrastructure
• Rising demand for alpha-emitters such as Ac-225 for advanced cancer therapy
• Government-led reactor modernization programs
• Digitization and automation in radiopharmaceutical production
• Growing clinical trials pipeline, attracting outsourcing from biotech start-ups

➤Key Player Strategies

• Investment in next-generation isotope production reactors and cyclotrons
• Collaborative R&D models with biotech innovators
• Establishment of region-specific GMP facilities to localize production
• Strategic M&A to acquire specialized radiochemistry technologies
• Strengthening cold-chain logistics and specialized transportation capabilities

Access Full Report for In-Depth Insights @https://www.custommarketinsights.com/report/radiopharmaceutical-cdmo-market/

➤Recent Developments

In October 2024, SpectronRx signed a binding agreement to build its first European radiolabeling plant at the Belgian Nuclear Research Center (SCK CEN) in Mol, with operations set to begin in early 2025 pending certification; the facility will primarily produce actinium-225-based radiopharmaceuticals, which are increasingly in demand for targeted cancer therapies across Europe, addressing supply shortages and supporting a pipeline of EMA-backed treatments. Leveraging its proprietary method for producing Ac-225 from multiple source elements, SpectronRx aims to manufacture these drugs at scale, further expanding on its global operations, which currently span five sites in 29 countries and involve collaborations with over 31 pharmaceutical firms and a workforce of about 150 employees.

➤Investment Landscape and ROI Outlook

The investment environment for radiopharmaceutical CDMOs is currently one of the strongest in the broader pharmaceutical manufacturing segment due to:

• High unmet demand for therapeutic isotopes
• Breakthrough efficacy of targeted radiotherapies
• Significant pharma outsourcing to specialized CDMOs
• Government investments in nuclear medicine infrastructure
• Venture capital interest in radiopharmaceutical start-ups

Return on investment (ROI) is expected to be strong, particularly for CDMOs focusing on:

• Actinium-225 production
• Lu-177 large-scale GMP manufacturing
• Cyclotron expansion programs
• Facility acquisitions in Europe and North America

Given the global shift toward personalized oncology, investors are positioned for both short-term revenue gains and long-term market expansion.

➤Market Segmentations

By Application

• Diagnostic Radiopharmaceuticals
• Therapeutic Radiopharmaceuticals

By Radioisotope Type

• Technetium-99m
• Fluorine-18
• Lutetium-177
• Gallium-68
• Actinium-225
• Others

By Source of Manufacturing

• Nuclear Reactors
• Cyclotrons

By Therapeutic Area

• Oncology
• Neurological Disorders
• Cardiovascular Disorders
• Others

By End-User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutions
• Hospitals & Nuclear Medicine Centers
• Others

➤Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific
The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa
Latin America
• Brazil
• Argentina
• Rest of Latin America

➤ Why Buy This Report?

• Comprehensive coverage of market size, trends, and competitive landscape
• Detailed segmentation across applications, isotopes, and end-users
• In-depth evaluation of key players, strategies, and global facility expansions
• High-value insights into regulatory frameworks and isotope supply chains
• Strategic intelligence to support investment decisions, partnerships, and market entry
• Up-to-date analysis of technological advancements and manufacturing innovations

➤FAQs

1. What is the expected market growth rate of the Radiopharmaceutical CDMO Market?
The market is forecasted to grow at a CAGR of 9.3% from 2025 to 2034.
2. What will be the market size by 2034?
The valuation is projected to reach USD 7.2 Billion.
3. Which radioisotopes are most in demand?
Technetium-99m, Fluorine-18, Lutetium-177, Gallium-68, and Actinium-225.
4. Who are the leading players?
NorthStar, Eckert & Ziegler, ITM, Curium, Cardinal Health, SOFIE, SpectronRx, Monrol, PharmaLogic, and others.
5. What is driving the surge in CDMO partnerships?
Complex radiopharmaceutical manufacturing, isotope shortages, expanding oncology pipelines, and the need for GMP-compliant nuclear medicine facilities.

➤ Explore More Related Market Reports by CMI -

Global Silicone Implant Market: CAGR 8.16%, from USD 2.75B (2024) to USD 5.15B (2033).
-https://www.custommarketinsights.com/report/silicone-implants-market/

Europe Cosmetic Surgery Market: CAGR 10.2%, from USD 23,853.7M (2024) to USD 57,172.8M (2033).
-https://www.custommarketinsights.com/report/europe-cosmetic-surgery-market/

About Custom Market Insights:

Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains.

CMI is a one-stop solution for data collection and investment advice. Our company's expert analysis digs out essential factors that help us understand the significance and impact of market dynamics. The professional experts advise clients on aspects such as strategies for future estimation, forecasting, opportunities to grow, and consumer surveys.

Contact Us:

Joel John
Custom Market Insights
1333, 701 Tillery Street Unit 12,
Austin, TX, Travis, US, 78702
US & Europe: +1 737 734 2707
APAC & Rest: +91 20 46022736
WhatsApp: +1 801-639-9061
Email: support@custommarketinsights.com
Web: https://www.custommarketinsights.com/

This release was published on openPR.